Cargando…

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia

The source and significance of residual low-level viremia (LLV) during combinational antiretroviral therapy (cART) remain a matter of controversy. It is unclear whether residual viremia depends on ongoing release of HIV from the latent reservoir or if viral replication contributes to LLV. We examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maggiolo, Franco, Di Filippo, Elisa, Comi, Laura, Callegaro, Annapaola, Colombo, Giorgio L, Di Matteo, Sergio, Valsecchi, Daniela, Rizzi, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457149/ https://www.ncbi.nlm.nih.gov/pubmed/28603436 http://dx.doi.org/10.2147/POR.S127974

Ejemplares similares

Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort
por: Maggiolo, Franco, et al.
Publicado: (2022)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
por: Maggiolo, Franco, et al.
Publicado: (2022)

Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation
por: Maggiolo, Franco, et al.
Publicado: (2015)

Early clinical response and presence of viral resistant minority variants: a proof of concept study
por: Callegaro, Annapaola, et al.
Publicado: (2014)

Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status
por: Maggiolo, Franco, et al.
Publicado: (2014)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy
por: Bakkour, Sonia, et al.
Publicado: (2020)

Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2021)

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia
por: Konstantopoulos, Christina, et al.
Publicado: (2015)

Predictors of Viremia in Postpartum Women on Antiretroviral Therapy
por: Hoffman, Risa M., et al.
Publicado: (2020)

Residual Viremia in Treated HIV(+) Individuals
por: Conway, Jessica M., et al.
Publicado: (2016)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
por: Mavigner, Maud, et al.
Publicado: (2009)

1564 Duration of Viral Suppression and objectively measured Antiretroviral Adherence as predictors of rebound Viremia in South Western Uganda
por: Musinguzi, Nicholas
Publicado: (2014)

Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
por: Ortíz, Dean W., et al.
Publicado: (2021)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
por: Mellberg, Tomas, et al.
Publicado: (2011)

Association of Residual Plasma Viremia and Intima-Media Thickness in Antiretroviral-Treated Patients with Controlled Human Immunodeficiency Virus Infection
por: Boyd, Anders, et al.
Publicado: (2014)

Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
por: Hofstra, Laura Marije, et al.
Publicado: (2014)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
por: Jacobs, Jana L., et al.
Publicado: (2019)

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
por: Archin, Nancie M., et al.
Publicado: (2010)

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy
por: Cillo, Anthony R., et al.
Publicado: (2014)

Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy
por: Younas, Mehwish, et al.
Publicado: (2021)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)
por: Cheng, Chien-Yu, et al.
Publicado: (2014)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
por: Weissmann, Leonardo, et al.
Publicado: (2019)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2011)

Effects of viremia and CD4 recovery on gut “microbiome-immunity” axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy
por: Russo, Edda, et al.
Publicado: (2022)

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy
por: Jacobs, Jana L., et al.
Publicado: (2020)

Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia
por: Sokpa, Darryl, et al.
Publicado: (2022)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
por: Llibre, Josep M, et al.
Publicado: (2013)

Cardiovascular Profile of South African Adults with Low-Level Viremia during Antiretroviral Therapy
por: Botha-Le Roux, Shani, et al.
Publicado: (2022)

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
por: Gagliardini, Roberta, et al.
Publicado: (2018)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
por: Lukhwareni, Azwidowi, et al.
Publicado: (2020)

Antiretroviral Treatment-Induced Galectin-9 Might Impact HIV Viremia in Addition to Contributing to Inflammaging
por: Shete, Ashwini, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2755323r1q43kvtn1sokc82i3r